Covid Alert

Print ISSN:-2581-4699

Online ISSN:-2581-4702


Current Issue

Year 2020

Volume: 6 , Issue: 2

Article Access statistics

Viewed: 628

Emailed: 0

PDF Downloaded: 236

IP International Journal of Medical Paediatrics and Oncology

Efficacy of levetiracetam in neonatal seizures, a prospective open label comparative study

Full Text PDF Share on Facebook Share on Twitter

Author Details : R. H. Gobbur, G. Gaduputi

Volume : 4, Issue : 1, Year : 2018

Article Page : 16-19

Suggest article by email


Objective: This study compares the efficacy of levetiracetam with phenobarbital in early onset seizures in term, late preterm neonates.
Design: Prospective randomized, open label comparative study.
Setting: study was carried out in tertiary care teaching hospital of
south India.
Participants: 78 terms, and late preterm neonates admitted in NICU with neonatal seizures.
Intervention: Neonates with seizures, were randomized into 2 groups to receive levetiracetam or phenobarbital as 1st line anti consultant in each group.
Results: As 1st line anti epileptic drug (AED) levetiracetam (LEV) was effective in 16 patients (41%), and phenobarbital was effective in19 patients (48.7%), where P value was not significant. But mortality was more in phenobarbital group with death of 10 patients (25.6%), and in LEV group death was only in 3 patients (7.7%) statistically significant (P value of 0.033).
Conclusion: levetiracetam and phenobarbital attained seizure control in less than 50% patients, both were equally effective, levetiracetam as 1st line anticonvulsant in early neonatal seizures leads to early seizure control and less mortality than use of phenobarbital.

Keywords: Levetiracetam, Neonatal Seizures.

Doi : 10.18231/2455-6793.2018.0006

How to cite : Gobbur R H, Gaduputi G, Efficacy of levetiracetam in neonatal seizures, a prospective open label comparative study. IP Int J Med Paediatr Oncol 2018;4(1):16-19

Copyright © 2018 by author(s) and IP Int J Med Paediatr Oncol. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC-BY-NC 4.0) (